BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer

Abstract BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 2024-11, Vol.45 (11), p.857-867
Hauptverfasser: Tokuyama, Shinji, Kato, Hisakazu, Takahashi, Hidekazu, Ueda, Kyoko, Arita, Asami, Ueda, Ryuta, Seto, Hiroto, Sekido, Yuki, Hata, Tsuyoshi, Hamabe, Atsushi, Ogino, Takayuki, Miyoshi, Norikatsu, Uemura, Mamoru, Matsuoka, Ken, Tsukamoto, Osamu, Yamamoto, Hirofumi, Doki, Yuichiro, Eguchi, Hidetoshi, Takashima, Seiji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 867
container_issue 11
container_start_page 857
container_title Carcinogenesis (New York)
container_volume 45
creator Tokuyama, Shinji
Kato, Hisakazu
Takahashi, Hidekazu
Ueda, Kyoko
Arita, Asami
Ueda, Ryuta
Seto, Hiroto
Sekido, Yuki
Hata, Tsuyoshi
Hamabe, Atsushi
Ogino, Takayuki
Miyoshi, Norikatsu
Uemura, Mamoru
Matsuoka, Ken
Tsukamoto, Osamu
Yamamoto, Hirofumi
Doki, Yuichiro
Eguchi, Hidetoshi
Takashima, Seiji
description Abstract BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignant transformation of cells; however, the mechanism underlying this impairment in cancer remains unknown. Here, we evaluated the responses of BRAFV600E-induced DDRs in two CRC cell lines, SW48 and LIM1215, both of which harbor wild-type TP53, KRAS, and BRAF. BRAFV600E transduction exhibited distinct phenotypes in these cells: SW48 cell proliferation markedly decreased, whereas that of LIM1215 increased. BRAFV600E expression induced the activation of oncogene-induced DDR signaling in SW48 cells, but not in LIM1215 cells, whereas chemotherapeutic agents similarly activated DDRs in both cell lines. Knockdown experiments revealed that these responses in SW48 cells were mediated by p53-p21 pathway activation. Comet assay (both alkaline and neutral) revealed that BRAFV600E increased single-strand breaks to the same extent in both cell lines; however, in the case of LIM1215 cells, it only facilitated double-strand breaks. Furthermore, the proliferation of LIM1215 cells, wherein no oncogene-induced DDRs occurred, was synergistically inhibited upon MDM2 inhibitor-mediated p53 activation combined with MEK inhibition. Taken together, these distinct DDR signaling responses highlight the novel characteristics of BRAFV600E-mutated CRC cells and define the therapeutic potential of p53 activation combined with MAPK inhibition against TP53 wild-type CRC harboring a BRAFV600E mutation. We showed that BRAFV600E expression induced distinct DNA damage responses in two colorectal cancer cell lines. BRAFV600E -induced DDR in SW48 cells is mediated by the p53-p21 pathway. MEK inhibition and p53 activation have a synergistic effect on DDR-defective LIM1215 cells. Graphical Abstract Graphical Abstract
doi_str_mv 10.1093/carcin/bgae040
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3067911530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/carcin/bgae040</oup_id><sourcerecordid>3067911530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-6ae5e73370ee4d385acbc2d4c308ac27ed61823d08214bd12aa6497520c9d43a3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQQC1ERZfClSPyEQ5px7HzdVxKC0gVVFXhGs2OJ8VV1g62U9R_wM8m1W577WE00ujNOzwh3ik4VtDpE8JIzp9sbpDBwAuxUqaGolQtvBQrUEYXWmtzKF6ndAugal11r8Shbtu67ZpuJf59ulqfy181wFnhvJ2JrbQuZecpy8_f19LiFm9YRk5T8Iml5cF5TjL_5oeJOPGcHckpZPbZ4SjDIKdKS6Ts7jC74OUQory-XG5_3WiLfD-xpDCGyJQXntATxzfiYMAx8dv9PhI_z8-uT78WFz--fDtdXxRUKpOLGrniRusGmI3VbYW0odIa0tAilQ3bWrWlttAu-MaqErE2XVOVQJ01GvWR-LDzTjH8mTnlfusS8Tii5zCnXkPddEpVGhb0eIdSDClFHvopui3G-15B_1C_39Xv9_WXh_d797zZsn3CH3MvwMcdEObpOdl_gSGQwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067911530</pqid></control><display><type>article</type><title>BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Tokuyama, Shinji ; Kato, Hisakazu ; Takahashi, Hidekazu ; Ueda, Kyoko ; Arita, Asami ; Ueda, Ryuta ; Seto, Hiroto ; Sekido, Yuki ; Hata, Tsuyoshi ; Hamabe, Atsushi ; Ogino, Takayuki ; Miyoshi, Norikatsu ; Uemura, Mamoru ; Matsuoka, Ken ; Tsukamoto, Osamu ; Yamamoto, Hirofumi ; Doki, Yuichiro ; Eguchi, Hidetoshi ; Takashima, Seiji</creator><creatorcontrib>Tokuyama, Shinji ; Kato, Hisakazu ; Takahashi, Hidekazu ; Ueda, Kyoko ; Arita, Asami ; Ueda, Ryuta ; Seto, Hiroto ; Sekido, Yuki ; Hata, Tsuyoshi ; Hamabe, Atsushi ; Ogino, Takayuki ; Miyoshi, Norikatsu ; Uemura, Mamoru ; Matsuoka, Ken ; Tsukamoto, Osamu ; Yamamoto, Hirofumi ; Doki, Yuichiro ; Eguchi, Hidetoshi ; Takashima, Seiji</creatorcontrib><description>Abstract BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignant transformation of cells; however, the mechanism underlying this impairment in cancer remains unknown. Here, we evaluated the responses of BRAFV600E-induced DDRs in two CRC cell lines, SW48 and LIM1215, both of which harbor wild-type TP53, KRAS, and BRAF. BRAFV600E transduction exhibited distinct phenotypes in these cells: SW48 cell proliferation markedly decreased, whereas that of LIM1215 increased. BRAFV600E expression induced the activation of oncogene-induced DDR signaling in SW48 cells, but not in LIM1215 cells, whereas chemotherapeutic agents similarly activated DDRs in both cell lines. Knockdown experiments revealed that these responses in SW48 cells were mediated by p53-p21 pathway activation. Comet assay (both alkaline and neutral) revealed that BRAFV600E increased single-strand breaks to the same extent in both cell lines; however, in the case of LIM1215 cells, it only facilitated double-strand breaks. Furthermore, the proliferation of LIM1215 cells, wherein no oncogene-induced DDRs occurred, was synergistically inhibited upon MDM2 inhibitor-mediated p53 activation combined with MEK inhibition. Taken together, these distinct DDR signaling responses highlight the novel characteristics of BRAFV600E-mutated CRC cells and define the therapeutic potential of p53 activation combined with MAPK inhibition against TP53 wild-type CRC harboring a BRAFV600E mutation. We showed that BRAFV600E expression induced distinct DNA damage responses in two colorectal cancer cell lines. BRAFV600E -induced DDR in SW48 cells is mediated by the p53-p21 pathway. MEK inhibition and p53 activation have a synergistic effect on DDR-defective LIM1215 cells. Graphical Abstract Graphical Abstract</description><identifier>ISSN: 0143-3334</identifier><identifier>ISSN: 1460-2180</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgae040</identifier><identifier>PMID: 38868979</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Cell Line, Tumor ; Cell Proliferation ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; DNA Damage ; Humans ; Mutation ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins c-mdm2 - antagonists &amp; inhibitors ; Proto-Oncogene Proteins c-mdm2 - genetics ; Proto-Oncogene Proteins c-mdm2 - metabolism ; Signal Transduction ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Carcinogenesis (New York), 2024-11, Vol.45 (11), p.857-867</ispartof><rights>The Author(s) 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c214t-6ae5e73370ee4d385acbc2d4c308ac27ed61823d08214bd12aa6497520c9d43a3</cites><orcidid>0000-0003-4619-3680 ; 0000-0003-1113-8884 ; 0000-0002-2318-1129 ; 0000-0003-2878-5391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38868979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tokuyama, Shinji</creatorcontrib><creatorcontrib>Kato, Hisakazu</creatorcontrib><creatorcontrib>Takahashi, Hidekazu</creatorcontrib><creatorcontrib>Ueda, Kyoko</creatorcontrib><creatorcontrib>Arita, Asami</creatorcontrib><creatorcontrib>Ueda, Ryuta</creatorcontrib><creatorcontrib>Seto, Hiroto</creatorcontrib><creatorcontrib>Sekido, Yuki</creatorcontrib><creatorcontrib>Hata, Tsuyoshi</creatorcontrib><creatorcontrib>Hamabe, Atsushi</creatorcontrib><creatorcontrib>Ogino, Takayuki</creatorcontrib><creatorcontrib>Miyoshi, Norikatsu</creatorcontrib><creatorcontrib>Uemura, Mamoru</creatorcontrib><creatorcontrib>Matsuoka, Ken</creatorcontrib><creatorcontrib>Tsukamoto, Osamu</creatorcontrib><creatorcontrib>Yamamoto, Hirofumi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Takashima, Seiji</creatorcontrib><title>BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>Abstract BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignant transformation of cells; however, the mechanism underlying this impairment in cancer remains unknown. Here, we evaluated the responses of BRAFV600E-induced DDRs in two CRC cell lines, SW48 and LIM1215, both of which harbor wild-type TP53, KRAS, and BRAF. BRAFV600E transduction exhibited distinct phenotypes in these cells: SW48 cell proliferation markedly decreased, whereas that of LIM1215 increased. BRAFV600E expression induced the activation of oncogene-induced DDR signaling in SW48 cells, but not in LIM1215 cells, whereas chemotherapeutic agents similarly activated DDRs in both cell lines. Knockdown experiments revealed that these responses in SW48 cells were mediated by p53-p21 pathway activation. Comet assay (both alkaline and neutral) revealed that BRAFV600E increased single-strand breaks to the same extent in both cell lines; however, in the case of LIM1215 cells, it only facilitated double-strand breaks. Furthermore, the proliferation of LIM1215 cells, wherein no oncogene-induced DDRs occurred, was synergistically inhibited upon MDM2 inhibitor-mediated p53 activation combined with MEK inhibition. Taken together, these distinct DDR signaling responses highlight the novel characteristics of BRAFV600E-mutated CRC cells and define the therapeutic potential of p53 activation combined with MAPK inhibition against TP53 wild-type CRC harboring a BRAFV600E mutation. We showed that BRAFV600E expression induced distinct DNA damage responses in two colorectal cancer cell lines. BRAFV600E -induced DDR in SW48 cells is mediated by the p53-p21 pathway. MEK inhibition and p53 activation have a synergistic effect on DDR-defective LIM1215 cells. Graphical Abstract Graphical Abstract</description><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>DNA Damage</subject><subject>Humans</subject><subject>Mutation</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Proto-Oncogene Proteins c-mdm2 - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins c-mdm2 - genetics</subject><subject>Proto-Oncogene Proteins c-mdm2 - metabolism</subject><subject>Signal Transduction</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0143-3334</issn><issn>1460-2180</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQQC1ERZfClSPyEQ5px7HzdVxKC0gVVFXhGs2OJ8VV1g62U9R_wM8m1W577WE00ujNOzwh3ik4VtDpE8JIzp9sbpDBwAuxUqaGolQtvBQrUEYXWmtzKF6ndAugal11r8Shbtu67ZpuJf59ulqfy181wFnhvJ2JrbQuZecpy8_f19LiFm9YRk5T8Iml5cF5TjL_5oeJOPGcHckpZPbZ4SjDIKdKS6Ts7jC74OUQory-XG5_3WiLfD-xpDCGyJQXntATxzfiYMAx8dv9PhI_z8-uT78WFz--fDtdXxRUKpOLGrniRusGmI3VbYW0odIa0tAilQ3bWrWlttAu-MaqErE2XVOVQJ01GvWR-LDzTjH8mTnlfusS8Tii5zCnXkPddEpVGhb0eIdSDClFHvopui3G-15B_1C_39Xv9_WXh_d797zZsn3CH3MvwMcdEObpOdl_gSGQwA</recordid><startdate>20241122</startdate><enddate>20241122</enddate><creator>Tokuyama, Shinji</creator><creator>Kato, Hisakazu</creator><creator>Takahashi, Hidekazu</creator><creator>Ueda, Kyoko</creator><creator>Arita, Asami</creator><creator>Ueda, Ryuta</creator><creator>Seto, Hiroto</creator><creator>Sekido, Yuki</creator><creator>Hata, Tsuyoshi</creator><creator>Hamabe, Atsushi</creator><creator>Ogino, Takayuki</creator><creator>Miyoshi, Norikatsu</creator><creator>Uemura, Mamoru</creator><creator>Matsuoka, Ken</creator><creator>Tsukamoto, Osamu</creator><creator>Yamamoto, Hirofumi</creator><creator>Doki, Yuichiro</creator><creator>Eguchi, Hidetoshi</creator><creator>Takashima, Seiji</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4619-3680</orcidid><orcidid>https://orcid.org/0000-0003-1113-8884</orcidid><orcidid>https://orcid.org/0000-0002-2318-1129</orcidid><orcidid>https://orcid.org/0000-0003-2878-5391</orcidid></search><sort><creationdate>20241122</creationdate><title>BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer</title><author>Tokuyama, Shinji ; Kato, Hisakazu ; Takahashi, Hidekazu ; Ueda, Kyoko ; Arita, Asami ; Ueda, Ryuta ; Seto, Hiroto ; Sekido, Yuki ; Hata, Tsuyoshi ; Hamabe, Atsushi ; Ogino, Takayuki ; Miyoshi, Norikatsu ; Uemura, Mamoru ; Matsuoka, Ken ; Tsukamoto, Osamu ; Yamamoto, Hirofumi ; Doki, Yuichiro ; Eguchi, Hidetoshi ; Takashima, Seiji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-6ae5e73370ee4d385acbc2d4c308ac27ed61823d08214bd12aa6497520c9d43a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>DNA Damage</topic><topic>Humans</topic><topic>Mutation</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Proto-Oncogene Proteins c-mdm2 - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins c-mdm2 - genetics</topic><topic>Proto-Oncogene Proteins c-mdm2 - metabolism</topic><topic>Signal Transduction</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tokuyama, Shinji</creatorcontrib><creatorcontrib>Kato, Hisakazu</creatorcontrib><creatorcontrib>Takahashi, Hidekazu</creatorcontrib><creatorcontrib>Ueda, Kyoko</creatorcontrib><creatorcontrib>Arita, Asami</creatorcontrib><creatorcontrib>Ueda, Ryuta</creatorcontrib><creatorcontrib>Seto, Hiroto</creatorcontrib><creatorcontrib>Sekido, Yuki</creatorcontrib><creatorcontrib>Hata, Tsuyoshi</creatorcontrib><creatorcontrib>Hamabe, Atsushi</creatorcontrib><creatorcontrib>Ogino, Takayuki</creatorcontrib><creatorcontrib>Miyoshi, Norikatsu</creatorcontrib><creatorcontrib>Uemura, Mamoru</creatorcontrib><creatorcontrib>Matsuoka, Ken</creatorcontrib><creatorcontrib>Tsukamoto, Osamu</creatorcontrib><creatorcontrib>Yamamoto, Hirofumi</creatorcontrib><creatorcontrib>Doki, Yuichiro</creatorcontrib><creatorcontrib>Eguchi, Hidetoshi</creatorcontrib><creatorcontrib>Takashima, Seiji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tokuyama, Shinji</au><au>Kato, Hisakazu</au><au>Takahashi, Hidekazu</au><au>Ueda, Kyoko</au><au>Arita, Asami</au><au>Ueda, Ryuta</au><au>Seto, Hiroto</au><au>Sekido, Yuki</au><au>Hata, Tsuyoshi</au><au>Hamabe, Atsushi</au><au>Ogino, Takayuki</au><au>Miyoshi, Norikatsu</au><au>Uemura, Mamoru</au><au>Matsuoka, Ken</au><au>Tsukamoto, Osamu</au><au>Yamamoto, Hirofumi</au><au>Doki, Yuichiro</au><au>Eguchi, Hidetoshi</au><au>Takashima, Seiji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2024-11-22</date><risdate>2024</risdate><volume>45</volume><issue>11</issue><spage>857</spage><epage>867</epage><pages>857-867</pages><issn>0143-3334</issn><issn>1460-2180</issn><eissn>1460-2180</eissn><abstract>Abstract BRAF V600E, one of the most frequent mutations in the MAPK pathway, confers poor prognosis to colorectal cancers (CRCs), partly because of chemotherapeutic resistance. Oncogene-induced DNA damage responses (DDRs) that primarily activate p53 are important mechanistic barriers to the malignant transformation of cells; however, the mechanism underlying this impairment in cancer remains unknown. Here, we evaluated the responses of BRAFV600E-induced DDRs in two CRC cell lines, SW48 and LIM1215, both of which harbor wild-type TP53, KRAS, and BRAF. BRAFV600E transduction exhibited distinct phenotypes in these cells: SW48 cell proliferation markedly decreased, whereas that of LIM1215 increased. BRAFV600E expression induced the activation of oncogene-induced DDR signaling in SW48 cells, but not in LIM1215 cells, whereas chemotherapeutic agents similarly activated DDRs in both cell lines. Knockdown experiments revealed that these responses in SW48 cells were mediated by p53-p21 pathway activation. Comet assay (both alkaline and neutral) revealed that BRAFV600E increased single-strand breaks to the same extent in both cell lines; however, in the case of LIM1215 cells, it only facilitated double-strand breaks. Furthermore, the proliferation of LIM1215 cells, wherein no oncogene-induced DDRs occurred, was synergistically inhibited upon MDM2 inhibitor-mediated p53 activation combined with MEK inhibition. Taken together, these distinct DDR signaling responses highlight the novel characteristics of BRAFV600E-mutated CRC cells and define the therapeutic potential of p53 activation combined with MAPK inhibition against TP53 wild-type CRC harboring a BRAFV600E mutation. We showed that BRAFV600E expression induced distinct DNA damage responses in two colorectal cancer cell lines. BRAFV600E -induced DDR in SW48 cells is mediated by the p53-p21 pathway. MEK inhibition and p53 activation have a synergistic effect on DDR-defective LIM1215 cells. Graphical Abstract Graphical Abstract</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>38868979</pmid><doi>10.1093/carcin/bgae040</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-4619-3680</orcidid><orcidid>https://orcid.org/0000-0003-1113-8884</orcidid><orcidid>https://orcid.org/0000-0002-2318-1129</orcidid><orcidid>https://orcid.org/0000-0003-2878-5391</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 2024-11, Vol.45 (11), p.857-867
issn 0143-3334
1460-2180
1460-2180
language eng
recordid cdi_proquest_miscellaneous_3067911530
source Oxford University Press Journals All Titles (1996-Current); MEDLINE
subjects Cell Line, Tumor
Cell Proliferation
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
DNA Damage
Humans
Mutation
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors
Proto-Oncogene Proteins c-mdm2 - genetics
Proto-Oncogene Proteins c-mdm2 - metabolism
Signal Transduction
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
title BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T01%3A37%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BRAF%20V600E-induced%20distinct%20DNA%20damage%20response%20defines%20the%20therapeutic%20potential%20of%20p53%20activation%20for%20TP53%20wild-type%20colorectal%20cancer&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Tokuyama,%20Shinji&rft.date=2024-11-22&rft.volume=45&rft.issue=11&rft.spage=857&rft.epage=867&rft.pages=857-867&rft.issn=0143-3334&rft.eissn=1460-2180&rft_id=info:doi/10.1093/carcin/bgae040&rft_dat=%3Cproquest_cross%3E3067911530%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067911530&rft_id=info:pmid/38868979&rft_oup_id=10.1093/carcin/bgae040&rfr_iscdi=true